Literature DB >> 35879537

Health-Economic Evaluation of the German Osteoporotic Fracture Prevention Program in Rural Areas (OFRA): Mobility and Falls Prevention Classes, Examination of Bone Health, and Consultation on Safety in the Living Environment.

Claudia Konnopka1, Gisela Büchele2, Dietrich Rothenbacher2, Patrick Roigk3, Kilian Rapp3, Hans-Helmut König4.   

Abstract

BACKGROUND: Fragility fractures are one of the leading causes of disability in older adults. Yet, evidence for effectiveness and cost-effectiveness of preventive approaches combining bone health and fall prevention is rare.
OBJECTIVE: To conduct a health-economic evaluation of the German osteoporotic fracture prevention program in rural areas (OFRA).
DESIGN: Secondary cluster-randomized intervention study based on routine data. PARTICIPANTS: All districts in five federal states in Germany were cluster-randomized as intervention or control districts. OFRA was offered to community-living (a) women aged 75-79 years or (b) women and men aged 70-84 years with a prior fragility fracture in the intervention districts. Individuals who meet these criteria in the control districts were assigned to the control group. INTERVENTION: OFRA comprised mobility and falls prevention classes, examination of bone health by bone density measurement, and consultation on safety in the home living environment. MAIN MEASURES: We measured health-care costs and effectiveness in terms of time to fragility fracture or death within 1 year after initial contact, based on health insurance claims data. Implementation costs were recorded by the intervention performers. We calculated an incremental cost-effectiveness ratio (ICER) and employed the net-benefit approach to construct a cost-effectiveness acceptability curve (CEAC). KEY
RESULTS: There were 9408 individuals in the intervention group and 27,318 in the control group. Mean time to fragility fracture or death (difference: 0.82 days) and health-care costs (difference: 111.73€, p < .01) were reduced, but mean intervention costs (difference: 260.10€) increased total costs (difference: 148.37€, p < .001) in the intervention group. The ICER per fracture-free year of survival was 66,094.63€. The CEAC showed no acceptable probability of cost-effectiveness at a reasonable willingness to pay.
CONCLUSION: OFRA showed reduced rates of fragility fractures, but had high implementation costs, resulting in an unfavorable ICER. The cost-effectiveness of OFRA may improve with a longer follow-up.
© 2022. The Author(s).

Entities:  

Keywords:  cost-effectiveness; fragility fractures; frailty; net-benefit approach; prevention

Year:  2022        PMID: 35879537     DOI: 10.1007/s11606-022-07691-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  4 in total

1.  Preventing injuries in older people by preventing falls: a meta-analysis of individual-level data.

Authors:  M Clare Robertson; A John Campbell; Melinda M Gardner; Nancy Devlin
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

2.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

Authors:  Ann Cranney; Gordon Guyatt; Lauren Griffith; George Wells; Peter Tugwell; Clifford Rosen
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

3.  Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle.

Authors:  K Akesson; D Marsh; P J Mitchell; A R McLellan; J Stenmark; D D Pierroz; C Kyer; C Cooper
Journal:  Osteoporos Int       Date:  2013-04-16       Impact factor: 4.507

4.  The osteoporotic fracture prevention program in rural areas (OFRA): a protocol for a cluster-randomized health care fund driven intervention in a routine health care setting.

Authors:  Kilian Rapp; Karin Kampe; Patrick Roigk; Hella Kircheisen; Clemens Becker; Ivonne Lindlbauer; Hans-Helmut König; Dietrich Rothenbacher; Gisela Büchele
Journal:  BMC Musculoskelet Disord       Date:  2016-11-08       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.